TOPAZ BIOSCIENCES, INC.
Endolysin enzymes that selectively lyse Cutibacterium acnes bacteria for topical acne treatment
- Sector
- Biotech
- Headquarters
- Emeryville, CA
- Founded
- 2022
- Latest Form D
- $1.4M, Mar 2025
- Total capital
- $3.5M
- Federal grants
- $2M
- 3 awards · 2023–2025
- Rank in peer group#397 of 514
- Private capital raised
- $1.4M
- 1 Form D · last Mar 2025
- 19 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 10 pending · first 2025
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris$1.5M
- Private capital raisedForm D · SEC · 1st filing$1.4M
- Federal grantHealth and Human S · Phase I · Metagenomic discovery and optimization of novel endolysins targeting Gardnerella vaginalis to treat bacterial vaginosis$300K
- Federal grantHealth and Human S · Phase I · Metagenomic discovery and optimization of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris$275K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
18months
from TOPAZ BIOSCIENCES, INC.’s first federal award to its first private round.
- First federal award · Sep 2023
- Health and Human S · $275K
- First Form D · Mar 2025
- $1.4M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#142 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jennifer ShockResearcherExecutive Officer, DirectorLinked by 1 patent
- Teresa ShockResearcherDirectorLinked by 1 patent
- Caroline HadfieldExecutive OfficerNamed in SEC Form D filings
- Oliver LiuExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 12- PendingCell Wall Hydrolases Targeting C. AcnesUSPTOApplication 19188859
- PendingEnzymatically Active Domains From Anti-staphylococcal Phage ProteinsUSPTOApplication 19390151
- PendingRecombinant Cell Wall HydrolasesUSPTOApplication 19061361
Show all 12 patent records
- Cell Wall Hydrolases Targeting C. AcnesMar 26, 2026 · Application 19188859Pending
- Enzymatically Active Domains From Anti-staphylococcal Phage ProteinsMar 19, 2026 · Application 19390151Pending
- Recombinant Cell Wall HydrolasesJan 8, 2026 · Application 19061361Pending
- Cell Wall Hydrolases Targeting C. AcnesMay 27, 2025 · US 12,312,617Granted
- Recombinant Cell Wall HydrolasesApr 1, 2025 · US 12,263,208Granted
- Cell Wall Hydrolases Targeting C. AcnesApplication 63529224Pending
- Recombinant Cell Wall HydrolasesApplication 63509160Pending
- Enzymatically Active Domains From Anti-staphylococcal Phage ProteinsApplication 63502341Pending
- Cell Wall Hydrolases Targeting C. AcnesApplication PCTUS2024039933Pending
- Recombinant Cell Wall HydrolasesApplication PCTUS2024034521Pending
- Enzymatically Active Domains From Anti-staphylococcal Phage ProteinsApplication PCTUS2024029487Pending
- Recombinant Cell Wall HydrolasesApplication 63639416Pending
Related companies, and why
- OYAGEN, INC.Similar federal contract value in Biotech · null in contracts
- PNA INNOVATIONS, INC.Similar federal contract value in Biotech · null in contracts
- Arrevus, Inc.Similar federal contract value in Biotech · null in contracts
- ACCURIUS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Goldilocks Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- ALLANDER BIOTECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .